Sight Sciences Q2 revenue $21.4M (-9% YoY); net loss $0.25/sh; FY guidance cut to $81M-$83M

Sight Sciences, Inc.

2024-Q2 EPS reported -$0.58 revenue$40,635,000

Total revenue $21.4M (-9% YoY); net loss $12.3M ($0.25/sh) vs $14.8M loss in Q2 2023.
Surgical Glaucoma revenue $20.2M (-5% YoY); Dry Eye revenue $1.1M (-46% YoY).
Cash used improved to $9.1M from $12.8M in Q2 2023; cash and equivalents $118.2M.
Narrowed FY2024 revenue guidance to $81M-$83M (0-2% growth) from prior $81M-$85M; adj. op. expenses $107M-$109M.
CMS proposes device-intensive status for OMNI procedure, which could increase ASC facility fee 29% in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.